A. Ricart

A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies

Amita Patnaik, A. Ricart, Jalyn Cooper et al. · Journal of Clinical Oncology · 2007 · 71 citations

Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling, T Kinetics +25

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

M. Mita, A. Ricart, Akira Mita et al. · Journal of Clinical Oncology · 2007 · 24 citations

Immunology, Immunoediting, Pathology +18

Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas

L. E. Raez, Virginia K. Langmuir, K. Tolba et al. · Journal of Clinical Oncology · 2007 · 16 citations

Glycolytic Inhibitor, Docetaxel Chemotherapy, Pharmacotherapy +18

A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM)

James Cooper, Monica Mita, J. Curtright et al. · Journal of Clinical Oncology · 2006 · 11 citations

Tumor Biology, Advanced Solid Malignancies, Medicine +15